ATE183085T1 - Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten - Google Patents
Behandlung und regulierung der augenentwicklung mit cholinergischen agonistenInfo
- Publication number
- ATE183085T1 ATE183085T1 AT94112616T AT94112616T ATE183085T1 AT E183085 T1 ATE183085 T1 AT E183085T1 AT 94112616 T AT94112616 T AT 94112616T AT 94112616 T AT94112616 T AT 94112616T AT E183085 T1 ATE183085 T1 AT E183085T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonist
- eye
- regulation
- treatment
- blocking
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36929389A | 1989-06-21 | 1989-06-21 | |
US07/522,241 US5122522A (en) | 1989-06-21 | 1990-05-11 | Treatment and control of ocular development |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE183085T1 true ATE183085T1 (de) | 1999-08-15 |
Family
ID=27004525
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT90911118T ATE147626T1 (de) | 1989-06-21 | 1990-06-14 | Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung |
AT96108497T ATE203666T1 (de) | 1989-06-21 | 1990-06-14 | Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung |
AT94112616T ATE183085T1 (de) | 1989-06-21 | 1990-06-14 | Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT90911118T ATE147626T1 (de) | 1989-06-21 | 1990-06-14 | Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung |
AT96108497T ATE203666T1 (de) | 1989-06-21 | 1990-06-14 | Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung |
Country Status (10)
Country | Link |
---|---|
US (2) | US5356892A (de) |
EP (1) | EP0478694B1 (de) |
JP (4) | JP3165436B2 (de) |
AT (3) | ATE147626T1 (de) |
CA (1) | CA2058768C (de) |
DE (3) | DE69033775T2 (de) |
DK (1) | DK0737475T3 (de) |
ES (2) | ES2136686T3 (de) |
HK (1) | HK1007681A1 (de) |
WO (1) | WO1990015604A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1336490C (en) * | 1988-06-03 | 1995-08-01 | Paul Michael Iuvone | Pharmacological treatment of ocular development |
ATE147626T1 (de) * | 1989-06-21 | 1997-02-15 | Univ Pennsylvania | Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung |
WO1993013777A1 (en) * | 1992-01-21 | 1993-07-22 | Merck & Co., Inc. | Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy |
US5716952A (en) * | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
US5385939A (en) * | 1993-04-30 | 1995-01-31 | The Trustees Of The University Of Pennsylvania | GABA-ergic modulation of eye growth |
US5756508A (en) * | 1995-10-31 | 1998-05-26 | Merck & Co., Inc. | Muscarine antagonists |
US6710051B1 (en) * | 1997-01-06 | 2004-03-23 | Klaus Trier Aps | Screening method |
US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
MXPA02007039A (es) * | 2000-01-18 | 2003-09-25 | Univ Pennsylvania | Crecimiento ocular y antagonistas nicotinicos. |
HUP0304071A2 (hu) * | 2001-05-25 | 2004-04-28 | Valley Forge Pharmaceuticals | Pirenzepine-tartalmú szemészeti gélkészítmény és eljárás az előállítására |
ITUB20160876A1 (it) | 2016-02-19 | 2017-08-19 | Dambrosio Enzo Maria | Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU188852B (en) * | 1983-03-16 | 1986-05-28 | Richter Gedeon Vegyeszeti Gyar Rt,Hu | Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer |
US4865599A (en) * | 1986-08-18 | 1989-09-12 | Houston Biotechnology, Inc. | Ophthalmic compositions for treating nerve degeneration |
CA1336490C (en) * | 1988-06-03 | 1995-08-01 | Paul Michael Iuvone | Pharmacological treatment of ocular development |
US5122522A (en) * | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
US5360801A (en) * | 1989-06-21 | 1994-11-01 | The Trustees Of The University Of Pennsylvania | Pharmacological stimulation of eye growth |
ATE147626T1 (de) * | 1989-06-21 | 1997-02-15 | Univ Pennsylvania | Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung |
US5055302A (en) * | 1990-02-22 | 1991-10-08 | Trustees Of The University Of Pennsylvania | Neuropeptide control of ocular growth |
US5385939A (en) * | 1993-04-30 | 1995-01-31 | The Trustees Of The University Of Pennsylvania | GABA-ergic modulation of eye growth |
-
1990
- 1990-06-14 AT AT90911118T patent/ATE147626T1/de not_active IP Right Cessation
- 1990-06-14 AT AT96108497T patent/ATE203666T1/de not_active IP Right Cessation
- 1990-06-14 DE DE69033775T patent/DE69033775T2/de not_active Expired - Fee Related
- 1990-06-14 EP EP90911118A patent/EP0478694B1/de not_active Expired - Lifetime
- 1990-06-14 ES ES94112616T patent/ES2136686T3/es not_active Expired - Lifetime
- 1990-06-14 ES ES96108497T patent/ES2159661T3/es not_active Expired - Lifetime
- 1990-06-14 DE DE69029734T patent/DE69029734T2/de not_active Expired - Fee Related
- 1990-06-14 DE DE69033246T patent/DE69033246T2/de not_active Expired - Fee Related
- 1990-06-14 CA CA002058768A patent/CA2058768C/en not_active Expired - Fee Related
- 1990-06-14 AT AT94112616T patent/ATE183085T1/de not_active IP Right Cessation
- 1990-06-14 JP JP51011290A patent/JP3165436B2/ja not_active Expired - Fee Related
- 1990-06-14 DK DK96108497T patent/DK0737475T3/da active
- 1990-06-14 WO PCT/US1990/003444 patent/WO1990015604A1/en active IP Right Grant
-
1992
- 1992-03-24 US US07/856,626 patent/US5356892A/en not_active Expired - Lifetime
-
1994
- 1994-06-29 US US08/268,035 patent/US5637604A/en not_active Expired - Fee Related
-
1998
- 1998-06-26 HK HK98106920A patent/HK1007681A1/xx not_active IP Right Cessation
-
2000
- 2000-02-17 JP JP2000039526A patent/JP3461778B2/ja not_active Expired - Fee Related
- 2000-07-11 JP JP2000210057A patent/JP2001081046A/ja active Pending
-
2003
- 2003-11-27 JP JP2003397487A patent/JP2004075695A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
HK1007681A1 (en) | 1999-04-23 |
DE69029734T2 (de) | 1997-05-28 |
ATE203666T1 (de) | 2001-08-15 |
ES2159661T3 (es) | 2001-10-16 |
US5637604A (en) | 1997-06-10 |
DE69033246D1 (de) | 1999-09-16 |
DE69029734D1 (de) | 1997-02-27 |
DK0737475T3 (da) | 2001-10-08 |
DE69033246T2 (de) | 1999-12-02 |
US5356892A (en) | 1994-10-18 |
JP2000204049A (ja) | 2000-07-25 |
JP2001081046A (ja) | 2001-03-27 |
JP2004075695A (ja) | 2004-03-11 |
DE69033775T2 (de) | 2001-11-15 |
ATE147626T1 (de) | 1997-02-15 |
JPH05500502A (ja) | 1993-02-04 |
DE69033775D1 (de) | 2001-09-06 |
CA2058768A1 (en) | 1990-12-22 |
EP0478694A1 (de) | 1992-04-08 |
EP0478694A4 (en) | 1992-07-29 |
EP0478694B1 (de) | 1997-01-15 |
JP3165436B2 (ja) | 2001-05-14 |
JP3461778B2 (ja) | 2003-10-27 |
WO1990015604A1 (en) | 1990-12-27 |
ES2136686T3 (es) | 1999-12-01 |
CA2058768C (en) | 2004-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6410544B1 (en) | Cholinergic agents in the treatment of presbyopia | |
Neufeld | Experimental studies on the mechanism of action of timolol | |
ATE183085T1 (de) | Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten | |
Trope et al. | Beta adrenergic receptors in pigmented ciliary processes. | |
EP0348360A3 (de) | Verwendung von Uridin zur Behandlung nervöser Störungen | |
KR920702622A (ko) | 안구 발육의 치료 및 조절 | |
DE68918099D1 (de) | Pharmazeutische behandlung einer augenentwicklung. | |
JPH08511024A (ja) | 眼内圧を低下させる方法および組成物 | |
AU655958B2 (en) | Use of quisqualate-receptor antagonists for treating Parkinson's disease | |
Stevens et al. | Are the pre-and postsynaptic α-adrenoceptors in human vascular smooth muscle atypical? | |
UA41329C2 (uk) | Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, похідні 3-фенілсульфоніл-3,7-діазабіцикло[3,3,1]нонану та лікарський засіб для лікування аритмії | |
Ferrari et al. | Behavioral effects induced by the dopamine D3 agonist 7-OH-DPAT in sexually-active and-inactive male rats | |
Joy et al. | Dose-dependent proconvulsant and anticonvulsant actions of the alpha2 adrenergic agonist, xylazine, on kindled seizures in the rat | |
CA2369054A1 (en) | Treatment and control of ocular development | |
Hurwitz et al. | The effects of the sympathetic nervous system on accommodation: II. Alpha sympathetic nervous system | |
Damase-Michel et al. | Effects of dopaminergic drugs on the sympathoadrenal system | |
Yonezawa et al. | α2-Adrenoceptor antagonists: effects on ejaculation, penile erection and pelvic thrusting behavior in dogs | |
ES473461A1 (es) | Un procedimiento para la preparacion de dibenzo (a,d) ci- cloocten-5,12 (6,12)-iminas y sus derivados | |
Moore et al. | Effects of N, N-dimethyltryptamine on electrically evoked responses in the cat visual system and modification by neuroleptic agents | |
Elena et al. | Characterization of β adrenergic receptors in bovine pigmented ciliary processes | |
JPS5572193A (en) | 9*100dihydroo4hhbenzo*4*5*cycloheptaa *1*22b*thiophenee4*99imine | |
Rengo et al. | Studies on the nature of the vasodilator fibers running in the lumbar sympathetic chain of the dog | |
Szalay et al. | Effect of beta adrenergic agents on blood vessels of the rat iris I. Permeability to carbon particles | |
Dickinson et al. | Effects of idazoxan on 5-hydroxytryptamine-mediated behaviour in the mouse and rat | |
KR890012651A (ko) | 이뇨제 또는 항고혈압제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |